1154 related articles for article (PubMed ID: 12677170)
21. Treatment of familial hypercholesterolemia with drugs in children.
Stein EA
Arteriosclerosis; 1989; 9(1 Suppl):I145-51. PubMed ID: 2912428
[TBL] [Abstract][Full Text] [Related]
22. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Yu L; Qiu S; Genest J
Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G
Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
Prager R
Wien Med Wochenschr Suppl; 1989; 105():17-20. PubMed ID: 2694627
[TBL] [Abstract][Full Text] [Related]
26. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell G
Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
[TBL] [Abstract][Full Text] [Related]
27. [Simvastatin in the treatment of hypercholesterolemia].
Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
[TBL] [Abstract][Full Text] [Related]
28. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
29. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
30. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
31. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
[TBL] [Abstract][Full Text] [Related]
32. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
Miltiadous G; Saougos V; Cariolou M; Elisaf MS
Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
[TBL] [Abstract][Full Text] [Related]
33. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
[TBL] [Abstract][Full Text] [Related]
34. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
35. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
36. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Hagemenas FC; Pappu AS; Illingworth DR
Eur J Clin Invest; 1990 Apr; 20(2):150-7. PubMed ID: 2112479
[TBL] [Abstract][Full Text] [Related]
37. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
Tomei R; Rossi L; Carbonieri E; Franceschini L; Cemin C; Ghebremariam-Tesfau K; Zardini P
Cardiologia; 1993 Dec; 38(12):773-8. PubMed ID: 8200011
[TBL] [Abstract][Full Text] [Related]
39. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
